Startup HAYA Hauls In $65M to Shed Light on the Dark Genome With a Lead Drug for Heart Failure

Startup HAYA Hauls In $65M to Shed Light on the Dark Genome With a Lead Drug for Heart Failure

HAYA Therapeutics’ drugs hit targets in the dark genome, the part of the genome that does not code for proteins but plays a key role in regulating gene expression. With the Series A funding, the startup will enter Phase 1 with of a genetic medicine addressing fibrosis that leads to a type of heart failure. The post Startup HAYA Hauls In $65M to Shed Light on the Dark Genome With a Lead Drug for Heart Failure appeared first on MedCity News.

Haya banks $65M to scour the ‘dark genome’ for new drugs

The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed by Bristol Myers and Cytokinetics.

Haya Therapeutics Raises $65M in Series A Funding

Haya Therapeutics, a Lausanne, Switzerland- and San Diego, CA-based biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases, raised $65m in Series A funding. The round was led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly and Company (Lilly), […] The post HAYA Therapeutics R…

HAYA Therapeutics gets $65M for 'dark genome' work following last year's Lilly pact

After working off $20 million in seed funding for about four years, HAYA Therapeutics tapped the funding well and came back with $65 million to get its cardiac fibrosis treatment candidate into human trials. ...

HAYA Therapeutics' $65M Series A Will Bring LncRNA Targeting Drugs to Clinic

If you still think that “junk DNA” is junk or that long noncoding RNAs (lncRNAs) are just a bunch of superfluous genome nonsense, well, you’re in for a rude awakening.  Clue #1: Big Pharma has made significant investments in this field, notably Eli Lilly in HAYA Therapeutics for up to $1 billion and Bayer in Dana-Farber spinout NextRNA for up to $547 million. Clue #2: The FDA has granted Orphan Drug Designation (ODD) to antisense oligonucleotide…